Japanese Enceph Vacc Sa14-14-2, Inactivated Dosage

Medically reviewed by Drugs.com. Last updated on Jan 3, 2025.

Usual Adult Dose for Japanese Encephalitis Virus Prophylaxis

Primary Series: Two 0.5 mL doses intramuscularly 28 days apart

Booster Dose: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.

Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.

Usual Pediatric Dose for Japanese Encephalitis Virus Prophylaxis

Primary Series:
3 years of age and older: Two 0.5 mL doses intramuscularly 28 days apart
2 months to less than 3 years of age: Two 0.25 mL doses intramuscularly 28 days apart

Booster Dose:
17 years of age and older: May give a booster dose if the primary 2 dose series was completed more than 1 year previously and ongoing exposure to Japanese encephalitis virus (JEV) is expected.
2 months to under 17 years: The safety and immunogenicity of a booster dose has not been evaluated.

Comments: The primary immunization series should be completed at least 1 week prior to potential exposure.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Severe allergic reactions (e.g. anaphylaxis) to any of the ingredients or to any other Japanese encephalitis virus vaccine
• Consider an allergist referral for patients allergic to another Japanese encephalitis vaccine to determine if this vaccine is appropriate; uncertainty is possible as to which vaccine component lead to the allergic reaction.

Safety and efficacy have not been established in patients younger than 2 months.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer intramuscularly
• Do not administer intravenously, intradermally or subcutaneously
• Preferred sites for IM injection: The anterolateral aspect of the thigh in infants 2 to 11 months of age, the anterolateral aspect of the thigh or the deltoid muscle (if muscle mass is adequate) in children 1 to less than 3 years of age, or the deltoid muscle in individuals 3 years of age and older

Storage requirements:

• Refrigerate; do not freeze
• Store in the original packaging to protect from light.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer